Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer
Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its Phase 2 Harmonic clinical trial., evaluating LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients who have relapsed after tyrosine kinase inhibitor (TKI) therapy.
Cover photo: RichieChan
Topics: Clinical Trials